TERN Terns Pharmaceuticals, Inc.

Nasdaq ternspharma.com


$ 7.78 $ -0.08 (-1.02 %)    

Monday, 27-Oct-2025 11:33:23 EDT
QQQ $ 626.54 $ 0.00 (0 %)
DIA $ 474.53 $ -0.26 (-0.05 %)
SPY $ 683.45 $ 0.67 (0.1 %)
TLT $ 91.36 $ 0.05 (0.05 %)
GLD $ 366.80 $ -4.14 (-1.12 %)
$ 7.77
$ 7.85
$ 7.76 x 169
$ 7.78 x 62
$ 7.66 - $ 8.08
$ 1.87 - $ 9.03
1,843,201
na
679.96M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-07-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-terns-pharma-lowers-price-target-to-15

JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and lowers the price ta...

 why-is-terns-pharmaceuticals-stock-trading-lower-after-obesity-trial-data

Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but repo...

 barclays-maintains-overweight-on-terns-pharma-lowers-price-target-to-14

Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and lowers the price target from $15 to...

 terns-pharma-reports-topline-12-week-results-from-phase-2-trial-of-tern-601-once-daily-oral-glp-1-receptor-agonist-as-potential-treatment-for-obesity

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic,...

 truist-securities-initiates-coverage-on-terns-pharma-with-buy-rating-announces-price-target-of-20

Truist Securities analyst Srikripa Devarakonda initiates coverage on Terns Pharma (NASDAQ:TERN) with a Buy rating and announ...

 barclays-initiates-coverage-on-terns-pharma-with-overweight-rating-announces-price-target-of-15

Barclays analyst Etzer Darout initiates coverage on Terns Pharma (NASDAQ:TERN) with a Overweight rating and announces Price ...

 hc-wainwright--co-assumes-terns-pharma-at-neutral-announces-price-target-of-744

HC Wainwright & Co. analyst Andrew S. Fein assumes Terns Pharma (NASDAQ:TERN) with a Neutral rating and announces Price ...

 eli-lillys-rare-weight-loss-data-miss-could-benefit-competitors

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising ...

 terns-pharma-q2-eps-026-beats-030-estimate

Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) ...

 terns-pharma-to-highlight-data-from-completed-phase-1-study-of-tern-601-once-daily-oral-glp-1r-agonist-at-ada-scientific-sessions

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in Septembe...

 terns-pharmaceuticals-selected-for-oral-presentation-at-eha-congress-for-preclinical-data-on-novel-allosteric-bcr-abl-inhibitor-tern-701

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including dif...

 bmo-capital-maintains-outperform-on-terns-pharma-lowers-price-target-to-15

BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and lowers the price target from $26...

 terns-pharma-q1-eps-026-beats-028-estimate

Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION